Forum Topics ILA ILA Bases are loaded, Ebola is at

Pinned straw:

Added a month ago

Today’s announcement is for the addition of another key person to help Island conduct the upcoming animal trials and obtain government funding support. However, the most interesting part is in the Q&A section at the bottom (do read) where Galidesivir’s relevance to the current Ebola strain outbreak is covered.

1. Appointment of Raymond Taylor

  • Island has added former BioCryst executive Raymond Taylor as Senior Scientific Fellow to lead Galidesivir’s development.
  • He brings 40+ years of drug development experience, including 19 years at BioCryst where Galidesivir was originally advanced.
  • He has secured and managed over US$490m in US government biodefence funding, including US$125m in Strategic National Stockpile (SNS) procurement contracts.
  • This directly targets Island’s core value pathway: FDA Animal Rule approval plus non‑dilutive US funding and stockpiling.
  • Timing is important, with Animal Rule studies due to commence next quarter and US biodefence agencies already engaged.


2. Broad‑spectrum profile and Ebola relevance

  • Galidesivir is an adenosine nucleoside analogue that inhibits the conserved viral RNA‑dependent RNA polymerase, giving activity across multiple RNA viruses including Marburg, Ebola and Sudan virus.
  • In primate models it has shown 94 percent survival in Marburg and 100 percent in Ebola versus zero in placebo, supporting its positioning as a leading filovirus countermeasure candidate.
  • This contrasts with existing Ebola Zaire–specific vaccines and monoclonal antibodies, which target strain‑specific surface glycoproteins and are ineffective against Ebola Bundibugyo.
  • The current Bundibugyo outbreak therefore crystallises a clear preparedness gap, emphasising the value of a broad‑spectrum antiviral such as Galidesivir.


If Island executes, Galidesivir has asymmetric upside via Animal Rule approval, SNS and allied stockpiling, and broader biodefence demand. Being a broad-spectrum treatment adds significantly value with increased utility across diseases and low/zero redundancy as new strains appear.

This is not new information, but we are now seeing the issue in a real world event which adds power to the proposition.

Disc: I own RL+SM

Tom73
Added a month ago

Additional notes – I asked my assistant for a simple non-scientific explanation of how Galidesivir works and what makes it different from non-broad based treatments. I think it did a good job and others will find useful:


Galidesivir is a man‑made chemical that closely resembles one of the basic “building blocks” that viruses use to copy their genetic material. When a virus is trying to multiply, it uses a special copying machine. Galidesivir sneaks into this process and jams that machine so the virus cannot keep making new copies of itself.

Because many dangerous viruses – including Marburg, Ebola and Sudan virus – all use a very similar copying machine, the same drug can interfere with many of them. That is why Galidesivir is called “broad spectrum”: it is designed to work against a wide range of related viruses, rather than being custom‑built for just one strain.

By contrast, most existing Ebola treatments and vaccines are like very specific keys made to fit one particular lock on the virus surface. If the virus surface changes enough – for example, a different Ebola species such as Bundibugyo – those keys no longer fit. Galidesivir targets the internal copying machinery instead, which is more similar across these viruses, so in principle it can still work even when the outside of the virus is different.

5